In this regard, MiM was noted in patients with all breast cancer subtypes, and, consistent with prior reports of MiM in other systemic malignancies,5–7,13–16 patients presented with nonspecific neurologic signs and symptoms. This evidence concerns the gene MTSS1 and breast carcinoma.